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Clinical Judgment of Differentiating the Diagnosis and 
Treatment of Schizophrenia and Schizoaffective Disorder 
 
Arjun Ughreja PharmD candidate1, Chloe Hwang PharmD candidate1, 
Jessica Goren BS, PharmD, BCPP1 
1The University of Rhode Island, College of Pharmacy 
Schizophrenia (SZ) is a disorder that is characterized by disordered 
thinking, memory, and perception in its patients. Schizoaffective 
disorder (SAD) is a separate disorder that features symptoms of 
schizophrenia and mood disorders. Because of the overlap in 
symptoms it is relatively easy to confuse schizoaffective disorder 
and schizophrenia. 
 
To be diagnosed with schizophrenia, patients must have at least two 
of the characteristic symptoms for a significant portion of time 
during a 1-month period and experience significant disturbance in 
functioning:1 
• delusions 
• hallucinations 
• disorganized speech 
• grossly disorganized or catatonic behavior 
• negative symptoms 
 
To be diagnosed with schizoaffective disorder, patients must exhibit 
the symptoms required for schizophrenia in addition to presenting 
with a major mood episode.1 
• elevated and depressed moods, with their associated 
symptoms 
 
Neither condition is preventable or curable, but various treatments 
exist for symptomatic suppression. However there are differences in 
how the two disorders are treated, so accurate diagnosing is 
imperative to ensure patients receive the appropriate evidence-
based treatment.  
Purpose 
Methodology 
1. Conduct semi-structured qualitative interviews with psychiatrists 
to understand how they diagnosis and treat patients with 
schizophrenia and schizoaffective disorders. 
2. For every psychiatrist interviewed, complete chart reviews of five 
of their patients with schizophrenia and schizoaffective disorder. 
3. Compare the real-world diagnosis and treatment of these patients 
with information gathered from the psychiatrists’ 
conceptualization of these disorders to explore patterns and 
trends associated with providing psychopharmaceutical care. 
Results Background 
• To understand how the diagnostic criteria on paper translates into 
real clinical practice 
• To develop interventions to improve the care of patients with 
schizophrenia and schizoaffective disorder. 
Table 1: Patient Baseline Characteristics Table 2:  Outcome Results 
Characteristic SZ 
n = 6 (%) 
SAD 
n = 29 (%) 
Gender   
 Female 3 (50%) 13 (44.8%) 
 Male 3 (50%) 16 (55.2%) 
Race   
 Caucasian 5 (83.3%) 18 (62.1%) 
 African American 0 4 (13.8%) 
 Hispanic 0 1 (3.4%) 
 Other 0 1 (3.4%) 
 Undefined 1 (16.7%) 5 (17.2%) 
Age (yrs)   
 < 25 0 1 (3.4%) 
 25-35 0 5 (17.2%) 
 35-45 0 2 (6.9%) 
 45-55 2 (33.3%) 8 (27.6%) 
 55-65 2 (33.3%) 8 (27.6%) 
 ≥ 65 2 (33.3%) 5 (17.2%) 
Alcohol Use   
 Never drank 1 (16.7%) 11 (37.9%) 
 Former drinker 0 4 (13.8%) 
 Current drinker 
Unknown 
1 (16.7%) 
4 (66.7%) 
6 (20.7%) 
8 (27.6%) 
Illegal Drug Use   
Never used 
Former user 
Current user 
Unknown 
1 (16.7%) 
0 
1 (16.7%) 
4 (66.7%) 
8 (27.6%) 
4 (13.8%) 
7 (24.1%) 
10 (34.5%) 
Housing   
 Lives alone 1 (16.7%) 6 (20.7%) 
 Lives with family/friends 1 (16.7%) 7 (24.1%) 
Lives in group home 
Lives in homeless shelter 
3 (50%) 
1 (16.7%) 
11 (37.9%) 
5 (17.2%) 
Prior Psych Hospitalizations 
Two or less 
Three - Four 
Five or more 
Unknown 
 
3 (50%) 
1 (16.7%) 
2 (33.3%) 
0 
 
6 (20.7%) 
6 (20.7%) 
16 (55.2%) 
1 (3.4%) 
 
Criteria SZ 
n = 6 (%) 
SAD 
n = 29 (%) 
Diagnosis 
Total # of patients before admission 6 (100%) 29 (100%) 
Total # of patients after admission 4 (66.6%) 29 (100%) 
# of change in diagnosis 2 (33.3%) 0 (0%) 
Treatment 
Total # of antipsychotics before admission 6 45 
Total # of antipsychotics after admission 7 40 
Average # of antipsychotics per patient 1.67 1.38 
Total # of mood stabilizers before admission 3 16 
Total # of mood stabilizers after admission 2 17 
Average # of mood stabilizers per patient 0.33 0.59 
Net improvement in mental status exam 
before vs. after hospitalization 
None = 0              Minimal < 2 
Moderate 2-4       Significant ≥ 5 
3.5 3.0 
Adherence 
Total # of long-acting medications prescribed 
at discharge 
2 (33.6%) 9 (31%) 
Total # of patients setup with outpatient 
medical supervision at discharge 
4 (66.6%) 21 (72.4%) 
 
• No diagnosis changes from SAD, while still possibly changing SZ 
to SAD, reflects how the psychiatrists conceptualized the 
distinction between diagnosing these two conditions 
• Majority of psychiatrists suggested SAD patients tend to have 
more success from therapy, opposite of the greater net 
improvement seen in SZ patients 
• Overall decrease in pill burden after admission implies that 
psychiatrists do work towards minimizing medications for patients 
• Majority of the psychiatrists reported preferring single agents and 
short-acting agents, unless adherence was compromised 
• 72.4% of SAD patients and 66.6% of SZ patients received 
adherence support, showing that psychiatrists helped more than 
half of their patients receive these services because of their great 
concern regarding continued patient adherence to therapy 
Long-acting 
injectable 
36% 
Visiting nurse 
29% 
Programs (counseling, 
psychoeducation) 
21% 
Formulation change 
14% 
Effective methods of improving adherence discussed by 
psychiatrists 
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Conclusion 
Preliminary trends have been evident as we proceed with our data 
analysis. The majority of psychiatrists did acknowledge a distinction 
between the two conditions and this distinction is supported by their 
diagnosing and treatment habits. However, they did not draw 
distinctions when discussing the issue of adherence, as almost all of 
them considered the lack of patient adherence as the main challenge 
of treatment. Larger and more structured studies are needed to 
further explore and confirm these findings.  
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